phase 1 trial
Recently Published Documents


TOTAL DOCUMENTS

617
(FIVE YEARS 175)

H-INDEX

59
(FIVE YEARS 13)

2022 ◽  
Author(s):  
Michael J. Koren ◽  
Patrick Maurice Moriarty ◽  
Seth J. Baum ◽  
Joel Neutel ◽  
Martha Hernandez-Illas ◽  
...  

Author(s):  
Jifang Gong ◽  
Junning Cao ◽  
Qingyuan Zhang ◽  
Nong Xu ◽  
Yanqiu Zhao ◽  
...  

Abstract Background This first-in-human phase 1 trial is to evaluate the safety, pharmacokinetics, preliminary efficacy, and biomarkers of sugemalimab, a full-length, fully human anti-PD-L1 monoclonal antibody, in Chinese patients with advanced malignancies. Methods Eligible patients with unresectable advanced or metastatic solid tumors or lymphomas were enrolled in phase 1a to receive sugemalimab following a modified 3 + 3 design. The primary endpoints included safety, tolerability, and the recommended Phase 2 dose (RP2D). In phase 1b, patients with 7 selected types of tumor received sugemalimab at the RP2D alone (monotherapy cohorts) or in combination with standard-of-care (SOC) chemotherapy (combination cohorts). The primary endpoint of phase 1b was investigator-assessed objective response rate (ORR). Results As of 19 February 2020, 29 and 178 patients were treated in phase 1a and 1b, respectively. No dose-limiting toxicities were observed in phase 1a, and the RP2D of sugemalimab was determined as 1200 mg fixed dose once every 3 weeks. Sugemalimab-related adverse events (AEs) were mostly (75.9%) grade 1–2 in phase 1a. Antitumor activity was observed across dose levels with an ORR of 24.1%. In phase 1b, 15.9% and 40.4% of patients in the monotherapy and combination cohorts, respectively, reported grade 3–5 sugemalimab-related AEs. Promising efficacy was observed in all combination cohorts, with ORRs ranging from 47.6 to 75.0%. Exploratory biomarker analysis did not indicate significant differences in responses at different PD-L1 expression/tumor mutation burden levels. Conclusions Sugemalimab was well-tolerated and showed promising antitumor activity as monotherapy or in combination with SOC chemotherapy in advanced malignancies. This trial was registered with ClinicalTrials.gov on Oct 18, 2017, number NCT03312842.


2022 ◽  
Author(s):  
Farid Boulad ◽  
Aurelio Maggio ◽  
Xiuyan Wang ◽  
Paolo Moi ◽  
Santina Acuto ◽  
...  

2021 ◽  
pp. 174701612110661
Author(s):  
Yasaswi Kislovskiy ◽  
Catherine Chappell ◽  
Emily Flaherty ◽  
Megan E Hamm ◽  
Flor de Abril Cameron ◽  
...  

Limited research has been done among pregnant people participating in investigational drug trials. To enhance the ethical understanding of pregnant people’s perspectives on research participation, we sought to describe motives and risk perceptions of participants in a phase 1 trial of ledipasvir/sofosbuvir (LDV/SOF) treatment for chronic Hepatitis C virus (HCV) during pregnancy. Pregnant people with chronic HCV infection enrolled in an open-label, phase 1 study of LDV/SOF participated in semi-structured, in-depth interviews to explore their reasons for participation and experiences within the study. Pregnant people took 12 weeks of LDV/SOF and were interviewed at enrollment and at the end of study. We recorded the interviews, transcribed them verbatim, coded them using NVivo software, and performed inductive thematic analysis. Nine women completed the study yielding 18 interview transcripts. We identified two themes regarding motives and one regarding risk perception. Motives—(1) Women conceptualized study participation as part of the caregiving role they associate with motherhood; participating was viewed as an act of caregiving for their infants, their families, themselves, and other pregnant women with chronic HCV. (2) Women also noted that they faced multiple barriers to treatment prior to pregnancy that created a desire to receive therapy through trial participation. Risk perception—(3) Women acknowledged personal and fetal risk associated with participation. Acceptance of risk was influenced by women’s concepts of motherhood, preexisting knowledge of HCV and medical research, family members, intimate partners, or by the study design. Women enrolled in a phase 1 trial for chronic HCV therapy during pregnancy acknowledged risks of participation and were motivated by hopes for fetal and personal benefit and by lack of prenatal access to treatment. Ethical inclusion of pregnant people in research should acknowledge structural factors that contribute to vulnerability and data deficiencies for treatment in pregnancy.


2021 ◽  
Author(s):  
Toshihiko Doi ◽  
Yasutoshi Kuboki ◽  
Yoichi Naito ◽  
Masahiro Ishida ◽  
Tetsuya Tanaka ◽  
...  

2021 ◽  
Vol 53 ◽  
pp. S664-S665
Author(s):  
J. Harsanyi ◽  
M. Kapás ◽  
Z. Juhasz ◽  
M.E. Rosa ◽  
G. Pasztor ◽  
...  

2021 ◽  
Author(s):  
Michael R. Olin ◽  
G. Elisabeth Pluhar ◽  
Ingunn Stromnes ◽  
Anne Eaton ◽  
Shannon Lynn ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document